Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Gastrointestinal Medicine
Volume 2018, Article ID 1015408, 5 pages
https://doi.org/10.1155/2018/1015408
Case Report

Tumor Necrosis Factor Alpha Inhibition for Inflammatory Bowel Disease after Liver Transplant for Primary Sclerosing Cholangitis

1Department of Gastroenterology and Hepatology, Henry Ford Health System, Detroit, MI, USA
2Department of Public Health Sciences, Henry Ford Health System, Detroit, MI, USA

Correspondence should be addressed to Nirmal Kaur; gro.shfh@1ruakn

Received 8 January 2018; Accepted 15 April 2018; Published 15 May 2018

Academic Editor: Warwick S. Selby

Copyright © 2018 Ravish Parekh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Bambha, W. R. Kim, J. Talwalkar et al., “Incidence, Clinical Spectrum, and Outcomes of Primary Sclerosing Cholangitis in a United States Community,” Gastroenterology, vol. 125, no. 5, pp. 1364–1369, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. O. Fausa, E. Schrumpf, and K. Elgjo, “Relationship of inflammatory bowel disease and primary sclerosing cholangitis,” Seminars in Liver Disease, vol. 11, no. 1, pp. 31–39, 1991. View at Publisher · View at Google Scholar · View at Scopus
  3. J. J. W. Tischendorf, H. Hecker, M. Krüger, M. P. Manns, and P. N. Meier, “Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study,” American Journal of Gastroenterology, vol. 102, no. 1, pp. 107–114, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. U. Broomé, R. Olsson, L. Lööf et al., “Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis,” Gut, vol. 38, no. 4, pp. 610–615, 1996. View at Publisher · View at Google Scholar · View at Scopus
  5. R. H. Wiesner, P. M. Grambsch, E. R. Dickson et al., “Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis,” Hepatology, vol. 10, no. 4, pp. 430–436, 1989. View at Publisher · View at Google Scholar · View at Scopus
  6. E. V. Loftus Jr., G. C. Harewood, C. G. Loftus et al., “PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis,” Gut, vol. 54, no. 1, pp. 91–96, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. J. F. Colombel, W. J. Sandborn, and W. Reinisch, “Infliximab, azathioprine, or combination therapy for Crohn's disease,” The New England Journal of Medicine, vol. 362, no. 15, pp. 1383–1395, 2010. View at Publisher · View at Google Scholar
  8. J. Costa, F. Magro, D. Caldeira, J. Alarcão, R. Sousa, and A. Vaz-Carneiro, “Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: A systematic review and meta-analysis,” Inflammatory Bowel Diseases, vol. 19, no. 10, pp. 2098–2110, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. A. B. Mohabbat et al., “Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients,” Alimentary pharmacology & therapeutics, vol. 36, no. 6, pp. 569–574, 2012. View at Google Scholar
  10. A. Sandhu, T. Alameel, C. H. Dale, M. Levstik, and N. Chande, “The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: A case series,” Alimentary Pharmacology & Therapeutics, vol. 36, no. 2, pp. 159–165, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Singh, E. V. Loftus, and J. A. Talwalkar, “Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis,” American Journal of Gastroenterology, vol. 108, no. 9, pp. 1417–1425, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. European FK506 Multicentre Liver Study Group, “Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection,” The Lancet, vol. 344, no. 8920, pp. 423–428, 1994. View at Publisher · View at Google Scholar · View at Scopus